Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
8.60
-0.23 (-2.60%)
Apr 29, 2026, 11:02 AM EDT - Market open
Kura Oncology Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 67.48 | 53.88 | - | - | - | Upgrade
|
| Revenue Growth (YoY) | 25.24% | - | - | - | - | Upgrade
|
| Cost of Revenue | 251.13 | 169.97 | 115.24 | 92.81 | - | Upgrade
|
| Gross Profit | -183.65 | -116.08 | -115.24 | -92.81 | - | Upgrade
|
| Selling, General & Admin | 119.98 | 77.11 | 50.57 | 47.05 | 46.54 | Upgrade
|
| Research & Development | - | - | - | - | 84.72 | Upgrade
|
| Operating Expenses | 119.98 | 77.11 | 50.57 | 47.05 | 131.26 | Upgrade
|
| Operating Income | -303.63 | -193.2 | -165.8 | -139.87 | -131.26 | Upgrade
|
| Interest Expense | -1.51 | -1.62 | -1.55 | -0.23 | -0.41 | Upgrade
|
| Interest & Investment Income | 18.29 | 9.71 | 5.3 | 5.86 | 5.6 | Upgrade
|
| EBT Excluding Unusual Items | -286.86 | -185.11 | -162.05 | -134.23 | -126.08 | Upgrade
|
| Gain (Loss) on Sale of Investments | 8.49 | 13.14 | 9.42 | -1.61 | -4.39 | Upgrade
|
| Pretax Income | -278.37 | -171.97 | -152.63 | -135.84 | -130.47 | Upgrade
|
| Income Tax Expense | 0.3 | 2.02 | - | - | - | Upgrade
|
| Net Income | -278.67 | -173.98 | -152.63 | -135.84 | -130.47 | Upgrade
|
| Net Income to Common | -278.67 | -173.98 | -152.63 | -135.84 | -130.47 | Upgrade
|
| Shares Outstanding (Basic) | 88 | 86 | 73 | 67 | 66 | Upgrade
|
| Shares Outstanding (Diluted) | 88 | 86 | 73 | 67 | 66 | Upgrade
|
| Shares Change (YoY) | 1.76% | 17.66% | 9.31% | 0.96% | 25.01% | Upgrade
|
| EPS (Basic) | -3.18 | -2.02 | -2.08 | -2.03 | -1.97 | Upgrade
|
| EPS (Diluted) | -3.18 | -2.02 | -2.08 | -2.03 | -1.97 | Upgrade
|
| Free Cash Flow | -70.7 | 133.85 | -124.99 | -110.69 | -105.7 | Upgrade
|
| Free Cash Flow Per Share | -0.81 | 1.55 | -1.71 | -1.65 | -1.59 | Upgrade
|
| Gross Margin | -272.14% | -215.44% | - | - | - | Upgrade
|
| Operating Margin | -449.94% | -358.54% | - | - | - | Upgrade
|
| Profit Margin | -412.95% | -322.89% | - | - | - | Upgrade
|
| Free Cash Flow Margin | -104.76% | 248.40% | - | - | - | Upgrade
|
| EBITDA | -302.6 | -192.35 | -164.96 | -139.11 | -130.7 | Upgrade
|
| D&A For EBITDA | 1.03 | 0.85 | 0.85 | 0.76 | 0.56 | Upgrade
|
| EBIT | -303.63 | -193.2 | -165.8 | -139.87 | -131.26 | Upgrade
|
| Revenue as Reported | 67.48 | 53.88 | - | - | - | Upgrade
|
| Advertising Expenses | 2.8 | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.